Navigation Links
Abbott, Genentech and WEHI Collaborate to Research and Develop New Anti-Cancer Drugs
Date:2/27/2008

MELBOURNE, Australia, Feb. 27 /PRNewswire/ -- The Walter and Eliza Hall Institute of Medical Research (WEHI) announced today that Abbott, a global, broad-based, healthcare company, Genentech, a leading biotechnology company based in South San Francisco and WEHI have joined in a tripartite research collaboration to discover new anti-cancer drugs.

"This exciting three party research collaboration among world leaders in this field may increase the chance of translating basic scientific research in apoptosis, the process of programmed cell death, as carried out by our collaborators over recent years, into novel targeted cancer therapeutics," says Dr. Julian Clark, Head of Business Development at WEHI.

"We are excited to collaborate with Abbott and Genentech based on their expertise in apoptosis and strong track records in the development of small molecule drugs. We believe both will be excellent collaborators in bringing forward potential novel cancer therapeutics that target the apoptosis pathway," explains WEHI cancer researcher, Dr. David Huang.

Under the terms of the collaboration the three parties are engaged in a drug discovery research program, with Genentech and Abbott being responsible for the development, manufacturing and commercialization of potential new drugs. The discovery stage of the collaboration involves an integrated approach engaging research sites in South San Francisco, the Chicago area and Melbourne. Financial terms of the collaboration will not be disclosed.

WEHI's director, Professor Suzanne Cory, emphasizes that "WEHI's first priority is to work to ensure that cancer patients benefit from the results of our fundamental research and all three parties in the collaboration are committed to the discovery and development of improved cancer treatments that enable patients to live longer and healthier lives."

Further information:

Dr. Julian Clark

Head Business Development WEHI: +61-3-9345-2612;

jclark@wehi.edu.au

Brad Allan

Communications Manager WEHI: +61-3-9345-2345

Mob +61-403036116


'/>"/>
SOURCE Walter and Eliza Hall Institute
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Genentech/Roches Lucentis and Eli Lillys Ruboxistaurin Will Drive the Diabetic Retinopathy and Nephropathy Drug Markets
2. Recovery Resources Collaborates with Two Nonprofit Agencies for Children of Alcoholics Outreach Program
3. MU researchers to collaborate on $20 million project
4. AHRQ and FDA to Collaborate in Largest Study Ever of Possible Heart Risks with ADHD Medications
5. The American Pain Foundation (APF) and The HealthCentral Network Collaborate to Develop Enhanced Internet Resources for People with Pain
6. EHRVA Members Collaborate to Demonstrate Interoperability Success at NCHICA
7. Rosecrance and Chicagos Department of Environment Collaborate to Help Families Dispose of Unwanted Medicines and Drugs
8. CIDM Collaborates With World Congress to Advance Dialog on Online Provider Networks at WHIT 3.0
9. Free Access to Literature Data on Chagas Disease Offered Online: Collaborative Drug Discovery, Inc. provides Neglected Disease researchers with archive mine and collaborate access to small molecule bioactivity SAR data on parasitic disease
10. SAIC to Collaborate with UK Biometrics Institute
11. General Motors, Virginia Tech scientists collaborate to advance neuroinformatics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
(Date:2/10/2016)... , ... February 10, 2016 , ... Ongoing news of ... Life Care Association™ (ALCA) to conduct a survey that takes a closer look at ... today illustrates the prevalence and causes of TBI among the aging population, and identifies ...
(Date:2/10/2016)... MA (PRWEB) , ... February 10, 2016 , ... Gout ... switch, and brings pain that is often severe, with intense swelling and redness. It ... than eight million people, but older adults are the most susceptible, according to the ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
(Date:2/10/2016)... ... 2016 , ... A national ergonomics pioneer , HealthPostures, ... March 9-11, 2016. Hosted by Ohio's Bureau of Worker's Compensation, the expo will ... running and largest worker's compensation event in Ohio, organizers of the safety congress ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... LONDON , February 10, 2016 ... window and M 1 receptor selectivity   ... Heptares StaR® technology, which has entered clinical development ... patients with dementia and schizophrenia.   --> ... StaR® technology, which has entered clinical development as ...
(Date:2/9/2016)... FARMINGDALE, N.Y., Feb. 9, 2016  Misonix, Inc. ... company that designs, manufactures and markets innovative therapeutic ... wound debridement, cosmetic surgery, laparoscopic surgery and other ... second quarter and the first half of fiscal ... --> --> Highlights ...
(Date:2/9/2016)... Mass. , Feb. 9, 2016  Insulet Corporation (NASDAQ: ... tubeless insulin pump technology with its OmniPod ... David A. Lemoine has been appointed to Insulet,s Board ... of nine directors, eight of whom are independent. ... 40 years of audit and finance experience and a deep ...
Breaking Medicine Technology: